Numerous clinical and animal studies have demonstrated strong up-regulation of activation fragments of complement components C1q, C3, and C4 in the serum, cerebrospinal fluid and neurological tissue (including spinal cord and motor cortex) of ALS patients and animal models of ALS [7–9]. This evidence concerns the gene C3 and amyotrophic lateral sclerosis.